Prevention of hepatocarcinogenesis after combinatoin therapy with daclatasvir and asunaprevir : A pilot study in usefulness of a small amount of Peg-interferon

Prevention of hepatocarcinogenesis after combinatoin therapy with daclatasvir and asunaprevir : A pilot study in usefulness of a small amount of Peg-interferon - Prevention of hepatocarcinogenesis after combinatoin therapy with daclatasvir and asunaprevir

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000018855

Enrollment

Registered

2015-10-01

Start date

2015-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Among genotye 1b HCV infected patients who achieved SVR in combination therapy with daclatasvir and asunaprevir, patients that serum AFP value is greater than or equal to 6.0 ng / mL at post-treatment 24 weeks

Interventions

45 micro gram of Pegylated interferon-alpha2a (Pegasys) is administered 12 times every four weeks

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Among patients who achieved SVR after combination therapy with daclatasvir and asunaprevir, patients that serum AFP value is greater than or equal to 6.0 ng / mL at post-treatment 24 weeks

Exclusion criteria

Exclusion criteria: patients with HCC

Design outcomes

Primary

Measure	Time frame
level of serum AFP	—

Countries

Japan

Contacts

Public ContactYoshihito Uchida

Saitama Medical University Department of Gastroenterology & Hepatology

y_uchida@saitama-med.ac.jp049-276-1198

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026